





PFIZER **Preparing for a healthier India**

For over 5 decades Pfizer is committed to working towards a healthier world.

RIGHT NOW, Pfizer is addressing public health challenges such as hypertension, launching innovative drugs in India and improving the quality of life in the community we live and work in.

Right now
Pfizer is caring for India's health



PFIZER **Stopping the blood loss in India**

RIGHT NOW, surgical procedures are inevitably associated with bleeding. Cyklokapron™, recently launched by Pfizer in India, will help reduce the risk of such blood loss.

Right now
Pfizer is caring for India's health

Report



Junction



PFIZER

Creating a breakthrough in India's health

RIGHT NOW, India has the 2nd largest number of smokers in the world*. As part of Pfizer's ongoing effort towards smoking cessation, we have launched Champix® in February 2008. This new-age drug is a breakthrough in this category.

Right now
Pfizer is caring for India's health

* WHO Report - Global Tobacco Epidemic, 2008

www.reportjunction.com



PFIZER
Making India less stressed


Report



Journal

RIGHT NOW, hypertension is one of the biggest public health challenges. Pfizer has released a potent weapon in the form of Acupil® in August 2008 to manage blood pressure.

Right now
Pfizer is caring for India's health



PFIZER

Innovating in animal health

Another addition to the companion animal business is Cantel. Cantel is a multi-spectrum dewormer for dogs of all life stages and is very effective for control of worms, ensuring they live healthier lives.

RIGHT NOW, feed efficiency and productivity of chickens are improving. With Netin® T in poultry, the industry now has in hand, the solution to fight life threatening diseases.

Right now
Pfizer is caring for India's health



PFIZER **Making India breathe**

RIGHT NOW, Pfizer is making a difference to patients with respiratory tract infections with Trulimax™. Azithromycin, the key component of Trulimax™ is the fifth largest molecule among antibiotics and is growing rapidly.

Right now
Pfizer is caring for India's health

PFIZER Making teams work together for a healthier India

RIGHT NOW, Pfizer colleagues
are determined by one single-
minded mission: work together
for a healthier world.

Our colleagues come from
different parts of India we speak
different languages and have
different traditions and customs.
But at Pfizer, we are driven by a
common purpose when it comes
to achieving the Company's
goals.

We all believe that, together, we
will improve the health of India.

Right now

Pfizer is caring for India's health



reportjunction.com



PFIZER
Caring about
community health in India

RIGHT NOW, we are striving to discover new medicines and are committed to improving the quality of life in the community we live and work in.

Caring for the Community is a core value at Pfizer. We are sensitive to the needs of the community, be it our response to Bihar Floods or endeavor to increase awareness of Glaucoma through the visual media centre.

Right now
Pfizer is caring for India's health

Report



Junction

www.reportjunction.com



Working together for a healthier world™

CONTENTS

NOTICE	4-6
DIRECTORS' REPORT INCLUDING MANAGEMENT DISCUSSION AND ANALYSIS REPORT	7-17
REPORT ON CORPORATE GOVERNANCE	18-26
AUDITORS' REPORT	27-31
BALANCE SHEET	32
PROFIT AND LOSS ACCOUNT	33
CASH FLOW STATEMENT	34-35
SCHEDULES	36-41
NOTES TO THE FINANCIAL STATEMENTS	42-60
REPORTS AND ACCOUNTS OF THE SUBSIDIARY COMPANY DUCHEM LABORATORIES LIMITED	61-72
CONSOLIDATED STATEMENT OF PFIZER LIMITED AND DUCHEM LABORATORIES LIMITED	73-96
PROXY CUM ATTENDANCE SLIP	97
CIRCULAR TO SHAREHOLDERS	99



Pfizer Limited: Ten Year Financial Summary

Rupees in Lakhs

	1999	2000	2001	2002†	2003	2004§	2005	2006	2007	2008
Sources of Funds										
Shareholders' Funds										
Share Capital	1172	2344*	2344	2344	2880	2880	2984	2984	2984	2984
Share Capital Suspense A/c	—	—	—	536	—	104	—	—	—	—
Reserves and Surplus	9541	11167	14645	27923	27960	31292	34672	37589	61880	86972
Total Shareholders' Funds	10713	13511	16989	30803	30840	34276	37656	40573	64864	89956
Borrowed Funds										
Secured Loans	—	—	—	—	—	—	—	—	—	—
Unsecured Loans	1	—	—	—	—	1200	—	—	—	—
Total	10714	13511	16989	30803	30840	35476	37656	40573	64864	89956
Application of Funds										
Net Fixed Assets	3502	3728	4210	5696	6110	7564	7770	6675	7040	8306
Investments	324	324	324	529	324	324	—	—	50	50
Deferred Tax Asset (Net)	—	310	503	790	989	636	903	1436	1298	2267
Current Assets, Loans and Advances:										
Inventories	4486	5780	5644	8484	8658	7389	8983	9845	9506	12468
Sundry Debtors	3810	3918	5421	12341	5883	7174	8282	6901	6137	5973
Cash and Bank Balances	2329	4609	5763	6840	8908	16110	20993	30651	47979	54306
Other Current Assets	—	—	—	—	45	137	214	903	817	1449
Loans & Advances	3839	3529	4289	7260	8330	6840	6693	6821	13537	24795
Total Current Assets, Loans and Advances	14464	17836	21117	34925	31824	37650	45165	55121	77976	98991
Less: Current Liabilities and Provisions										
Current Liabilities	5439	6771	6312	11112	9619	11284	13404	14495	10628	12214
Provisions	2376	2366	2853	5244	4192	5421	6448	9498	11165	7444
Net Current Assets	6649	8699	11952	18569	18013	20945	25313	31128	56183	79333
Misc. Expenditure (Deferred Revenue Expenditure)										
Voluntary Retirement Scheme	239	—	—	5219	5404	6007	3670	1334	293	—
Commercial Rights	—	450	—	—	—	—	—	—	—	—
Total	10714	13511	16989	30803	30840	35476	37656	40573	64864	89956
Income										
Gross sales	28733	32719	36207	65127	55896	65966	69750	76586	77301	76482
Less: Excise duty			3796	5719	3954	4884	5416	6039	6199	5409
Less: Sales tax			2643	5165	4478	5304	4482	4312	3836	3302
Net sales			29768	54243	47464	55778	59852	66235	67266	67771
Operating and other Income	5107	5162	6147	6007	4051	3924	4103	5953	34270	9342
Total	33840	37881	35915	60250	51515	59702	63955	72188	101536	77113
Expenditure										
Material Cost	8830	10066	10736	21978	19737	22370	20007	22356	23148	23759
Personnel Cost	4865	5056	5580	8784	7942	8255	10014	10234	10170	10210
Manufacturing and other expenses	14100	15774	11154	17183	16409	18564	19273	19746	20510	20966
Interest Expense	54	37	26	76	39	81	15	7	2	—
Depreciation	768	676	717	1064	1083	1026	1385	1307	958	1112
Total	28617	31609	28213	49085	45210	50296	50694	53650	54788	56047
Profit Before Taxation & Exceptional Items	5223	6272	7702	11165	6305	9406	13261	18538	46748	21066
Exceptional items - Net	—	—	—	1518	(1673)	(1922)	(2337)	(2337)	(1735)	20790
Profit Before Taxation	5223	6272	7702	12683	4632	7484	10924	16201	45013	41856
Taxation	2130	2518	2953	5089	1881	2932	4112	5628	11120	11944
Profit After Taxation	3093	3754	4749	7594	2751	4552	6812	10573	33893	29912
Tax Provision as % of PBT	40.8	40.1	38.3	40.1	40.6	39.2	37.6	34.7	24.7	28.5
Net Profit as % of Sales	10.8	11.5	13.1	11.7	4.9	6.9	9.8	13.8	50.3*	44.1**
Earnings per share (Rs.)	26.39	16.02@	20.26	26.37	9.55	15.25	22.83	35.43	113.58	100.24
Equity Dividend per share (Rs.)	5.00	4.00	5.00	7.50	7.50	10.00	10.00	22.50	27.50	12.50
Total Dividend Amount (Rs. in Lakhs)	586	938	1172	2160	2160	2984	2984	6714	8206	3730
Book Value per share (Rs.)	91.41	57.64@	72.48	106.95	107.08	114.86	126.19	135.95	217.37	301.46

* Increase due to issue of Bonus Shares in the ratio 1:1

@ Diluted due to issue of Bonus Shares in the ratio of 1:1

† Includes results of erstwhile Parke-Davis (India) Ltd. on its amalgamation with the Company

§ Includes results of erstwhile Pharmacia Healthcare Ltd. on its amalgamation with the Company

Includes profit on sale of Chandigarh property.

** Includes profit on sale of 4 consumer healthcare brands.